All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The FDA grants FATE-NK100 Investigational New Drug Application clearance for treatment of R/R AML
On 13th March 2017, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) application clearance for FATE-NK100, a first-in-class adaptive Natural Killer (NK) cell, for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1
FATE-NK100 is comprised of a highly specialized and functionally distinct subset of NK cells expressing the memory-like activating receptor NKG2C and the maturation marker CD57. In AML, NK cells have been shown to exert powerful anti-leukemic activity in preventing relapse.2 Preclinical data have demonstrated that FATE-NK100 can induce a robust formation of adaptive memory NK cells which have an enhanced anti-tumor activity and improved persistence. Additionally, FATE-NK100 have been shown to stimulate an endogenous T-cell response and also resist immune checkpoints. 1,3
The IND approval granted by the FDA allows FATE-NK100 to be evaluated in a first-in-human trial in R/R AML patients. This study will evaluate the safety and determine the maximum dose of intravenous infusion of FATE-NK100 in R/R patients. Additionally, Complete Response (CR), Disease Free Survival (DFS), and clearance of Minimal Residual Disease (MRD) would also be accessed secondarily. Enrollment into trials are anticipated to start at the Masonic Cancer Center, University of Minnesota, following approval of the Center’s institutional review board.1
References